Pharmaceutical companies just raised list prices for over 500 medicines, including Novo Nordisk’s Ozempic, Gilead’s HIV-1 ...

MSD's new drug combination shows promise in HIV-1 treatment, aiming to offset potential losses from Keytruda's patent ...

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet ...

Biktarvy contributed more than the other four on the list, the ICER's Vice President of Research Foluso Agboola said. The report disregarded evidence on Biktarvy, including data that prompted two ...

The company's Q3 earnings show strong performance in HIV treatments, with Biktarvy leading and new regimens expected by 2030, and upgraded 2024 guidance for >$28bn revenues, EPS of >$4.

In Q1 2024, Gilead recorded 4% revenue gains from the help of Biktarvy (indicated for HIV-1 infection) and their cell therapy products (e.g., Yescarta). I was also keeping a close eye on seladelpar.

The reversal comes after a state investigation and charges by advocacy groups that proposed policy changes would violate the Affordable Care Act. Harvard Pilgrim Health Care reversed a decision to ...

In HIV, its flagship therapy, Biktarvy, continues to maintain strong growth, thereby fueling the company’s top line, a trend expected to continue in 2025. The approval of new therapies like ...

Gilead’s HIV drug Biktarvy, Novartis’ heart drug Entresto, Exelixis’ cancer therapy Cabometyx and Pfizer’s rheumatoid arthritis drug Xeljanz were the other four drugs that contributed to ...